Loestrin 24 Fe was approved in February 2006 as an oral contraceptive. The primary mechanism of action is inhibition of ovulation, and other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation).